Anti-PD-L1 monoclonal antibody ( Apollomics/Chia Tai Tianqing Pharmaceutical Group)、PD-L1 antibody ( Apollomics/Chia Tai Tianqing Pharmaceutical Group)、APL 502

+ [7]

靶点

PDL1

作用方式

抑制剂、刺激剂

作用机制

PDL1抑制剂(程序性死亡配体1抑制剂)、T淋巴细胞刺激剂

治疗领域

肿瘤呼吸系统疾病泌尿生殖系统疾病+ [8]

在研适应症

肺泡软组织肉瘤晚期鳞状非小细胞肺癌非小细胞肺癌 III期+ [35]

非在研适应症

原研机构

在研机构

+ [1]

非在研机构

阿普络医药科技（浙江）有限公司

权益机构

阿普络医药科技（浙江）有限公司

正大天晴药业集团股份有限公司

最高研发阶段批准上市

首次获批日期

中国 (2024-04-30),

广泛期小细胞肺癌

最高研发阶段(中国)批准上市

特殊审评突破性疗法 (中国)、附条件批准 (中国)、优先审评 (中国)

登录后查看时间轴

结构/序列

Sequence Code 10067450H

来源: *****

Sequence Code 10067454L

来源: *****

关联

111

项与贝莫苏拜单抗相关的临床试验

NCT07849712

/ Not yet recruitingN/AIIT

Bemo-sufail Monoclonal Antibody Combined With Anlotinib As First-Line Treatment For Elderly Patients With Locally Advanced Or Metastatic Non-Small-Cell Lung Cancer: An Exploratory Clinical Study

This exploratory clinical study evaluates the efficacy and safety of combining benmelstobart (a PD-L1 inhibitor) with anlotinib (a multi-target anti-angiogenic TKI) as a first-line, chemotherapy-free treatment for elderly patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).

开始日期2026-10-01

申办/合作机构

浙江省肿瘤医院

NCT07728955

/ Not yet recruiting临床3期IIT

A Single-arm, Exploratory Clinical Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Anlotinib and Etoposide as First-line Therapy for Elderly Patients With Small-cell Lung Cancer or Those Who Are Intolerant to Intensive Chemotherapy

A single-arm exploratory clinical study to observe and evaluate the first-line treatment of elderly and treatment-intolerant patients with small cell lung cancer using benmelstobart in combination with anlotinib and etoposide.
Eligible patients are those with histologically or pathologically confirmed small cell lung cancer (SCLC) (AJCC 9th edition), who are treatment-naïve and considered elderly or intolerant to intensive therapy. Eligible subjects receive 4-6 cycles of benmelstobart injection combined with anlotinib hydrochloride and etoposide, followed by maintenance therapy with benmelstobart injection plus anlotinib hydrochloride, continued until disease progression or intolerable toxicity.
The study aims to evaluate the efficacy and safety of first-line treatment with benmelstobart injection in combination with anlotinib hydrochloride and etoposide in patients with advanced SCLC.

开始日期2026-08-01

申办/合作机构

中山大学孙逸仙纪念医院

NCT07602101

/ Not yet recruiting临床2期IIT

Neoadjuvant PD-L1 Blockade Combined With Anlotinib to Enable Nephron-Sparing Surgery in Patients With High-Complexity Locally Advanced Clear Cell Renal Cell Carcinoma

This is a prospective, multicenter, single-arm phase II study evaluating the efficacy and safety of neoadjuvant PD-L1 inhibitor TQB2450 in combination with anlotinib in patients with locally advanced, high-complexity (RENAL score ≥10) clear cell renal cell carcinoma (ccRCC).
The primary objective is to determine whether neoadjuvant therapy can increase the rate of successful nephron-sparing surgery.
In addition, this study incorporates a pre-specified translational research platform including circulating tumor DNA (ctDNA) methylation-based minimal residual disease (MRD) monitoring, tumor multi-omics profiling, and radiomics analysis. Artificial intelligence-based models will be developed to predict treatment response and surgical conversion, enabling precision neoadjuvant strategies.

开始日期2026-05-31

申办/合作机构

上海交通大学医学院附属仁济医院

[+2]

100 项与贝莫苏拜单抗相关的临床结果

登录后查看更多信息

100 项与贝莫苏拜单抗相关的转化医学

登录后查看更多信息

100 项与贝莫苏拜单抗相关的专利（医药）

登录后查看更多信息

225

项与贝莫苏拜单抗相关的文献（医药）

2026-10-01·COLLOIDS AND SURFACES B-BIOINTERFACES

Nanocomposites integrating antigen release and presentation for treatment of sarcoma

Article

作者: Wang, Qing ; Li, Wengang ; Zhou, Xiao ; Liu, Zhaohui ; Jiang, Jie ; Zheng, Jialiang ; Mi, Yanjun ; Wu, Jincheng ; Miao, Fenglin ; Geng, Guojun ; Tang, Mingkun

Soft-tissue sarcomas present a significant clinical challenge owing to their high postoperative recurrence rates and poor responsiveness to radiotherapy and chemotherapy. The insufficient infiltration of immune cells into the tumor microenvironment further limits the efficacy of immunotherapy. Photodynamic therapy (PDT) can induce immunogenic cell death (ICD) in tumor cells by releasing tumor-associated antigens. These antigens can be used to activate dendritic cells (DCs) in vitro and extract DC vesicles. These vesicles can activate T cells in a more effective and specific manner, promoting their maturation and tumor infiltration, thereby achieving effective tumor immunotherapy. After delivering photosensitizers to the tumor site via nanocarriers, the tumor antigens generated in situ by PDT can further enhance tumor accumulation and the anti-tumor immune response of these T cells. Based on this rationale, we developed a cell membrane-based nanoplatform that integrates PDT and T cell activation. Nanoparticles were fabricated by coating indocyanine green-loaded mesoporous polydopamine nanoparticles with a hybrid membrane derived from DCs activated by PDT-released antigens and tumor cells (DTM-MI). In vitro, DTM-MI demonstrated efficient tumor cell targeting and laser irradiation, produced abundant reactive oxygen species (ROS), and induced tumor cell death and release of ICD-related molecules. DTM-MI selectively accumulated in tumors of tumor-bearing mice in vivo Combined with PD-L1 antibody and laser irradiation, DTM-MI significantly inhibited tumor growth while elevating serum levels of immune-related cytokines, confirming anti-tumor immune activation. Lymph nodes showed increased T-cell and CD8 + T-cell populations, and tumor sites exhibited enhanced CD8 + T-cell and cytotoxic T lymphocyte (CTL) infiltration. The dual targeting of tumor cells and T cells by DTM-MI coupled with DC membrane-mediated T-cell activation and homing to PDT-treated regions facilitated potent tumor killing. Laser-triggered immunogenic cell death and antigen release further amplify T cell-mediated anti-tumor immunity, presenting a promising therapeutic approach for sarcomas.

2026-08-18·Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences

[Long-term survival achieved with benmelstobart plus anlotinib in a patient with advanced clear cell renal cell carcinoma: A case report].

Article

作者: Zhang, Jiaran ; Tian, Huichun ; Li, Juan

Clear cell renal cell carcinoma (ccRCC) is the most common histological subtype of renal cell carcinoma. Patients classified as intermediate- or poor-risk according to the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC), particularly those with multiple organ metastases, generally have an unfavorable prognosis. Here, we report a case of advanced ccRCC in an IMDC poor-risk patient who achieved an unexpectedly prolonged survival with combination therapy followed by maintenance immunotherapy. A 65-year-old male developed multiple metastases involving the lungs, liver, and bone shortly after undergoing radical nephrectomy for right-sided renal cancer. Laboratory findings revealed anemia, neutrophilia, and thrombocytosis, and the IMDC score was 5, indicating poor-risk disease. The patient received first-line treatment with the programmed death-ligand 1 (PD-L1) inhibitor benmelstobart in combination with the multi-target tyrosine kinase inhibitors (TKIs) anlotinib. After 6 weeks of therapy, radiological evaluation demonstrated a partial response (PR), with an overall tumor reduction of approximately 48%. Subsequent imaging assessments confirmed a durable PR, accompanied by significant improvement in clinical symptoms and performance status. During treatment, the patient developed progressive proteinuria, with a maximum 24-hour urinary protein level of 5.18 g. Despite stepwise dose reduction of anlotinib, proteinuria recurred, necessitating discontinuation of the TKIs. Following cessation of anlotinib, the patient continued benmelstobart monotherapy as maintenance therapy and maintained sustained deep remission. After approximately 3 years of treatment, serum creatinine levels gradually increased, reaching a peak of 228 μmol/L. Considering the possibility of treatment-related renal toxicity and the durable disease control achieved, immunotherapy was subsequently discontinued. No further antitumor treatment was administered. The patient eventually experienced disease progression and died in September 2024, with an overall survival of 44 months. This case suggests that the combination of benmelstobart and anlotinib can induce rapid and durable antitumor responses in patients with IMDC poor-risk advanced ccRCC. Notably, in patients who respond well to combination therapy, discontinuation of TKIs due to intolerable adverse events followed by maintenance immunotherapy may still provide long-term disease control. This sustained benefit may be associated with tumor microenvironment remodeling and the establishment of immunological memory induced by anti-angiogenic therapy. Furthermore, this case highlights the importance of vigilant monitoring of renal toxicity and individualized treatment adjustment during combined targeted therapy and immunotherapy.

2026-06-01·Translational Lung Cancer Research

Consolidation thoracic radiotherapy following quadruple induction with benmelstobart, anlotinib, and chemotherapy for extensive-stage small cell lung cancer: rationale and protocol of a phase II study

Article

作者: Sun, Jifeng ; Yu, Miao ; Liu, Ningbo ; Cui, Yong ; Zhou, Yuntao ; Zhu, Hui ; Liu, Jialei ; Yang, Chengwen ; Yang, Siyi

Background:

Extensive-stage small cell lung cancer (ES-SCLC) remains a highly aggressive malignancy with limited survival outcomes. While first-line immune checkpoint inhibitors combined with platinum-based chemotherapy have improved survival, the benefit is modest. Emerging evidence supports the integration of anti-angiogenic therapy and thoracic radiotherapy (TRT) to enhance systemic and local control. However, a comprehensive multimodal regimen combining chemotherapy, immunotherapy, anti-angiogenic therapy, and TRT has not been systematically evaluated. This study aims to assess the safety, feasibility, and preliminary efficacy of a multimodal treatment strategy involving induction with benmelstobart [an anti-programmed death-ligand 1 (PD-L1) antibody], platinum-etoposide chemotherapy, and anlotinib, followed by consolidation with benmelstobart, anlotinib, and sequential TRT in patients with untreated ES-SCLC.

Methods:

This is a prospective, single-center, single-arm, phase II, open-label trial conducted at Tianjin Medical University Cancer Institute & Hospital. Twenty-five patients with histologically confirmed, treatment-naive ES-SCLC and measurable disease per Response Evaluation Criteria in Solid Tumors, version 1.1 will be enrolled. The regimen consists of-induction phase: 4 cycles of benmelstobart (1,200 mg IV q21d), carboplatin (area under the curve 5) or cisplatin (75-80 mg/m²) on day 1, etoposide (100 mg/m² IV days 1-3), and oral anlotinib (12 mg once daily, 2 weeks on/1 week off); consolidation phase: 2 cycles of benmelstobart, anlotinib, and TRT (25 Gy in 5 daily fractions of 5 Gy each, administered only during the first consolidation cycle); maintenance phase: benmelstobart plus anlotinib until progression, unacceptable toxicity, or clinical deterioration. The co-primary endpoints are progression-free survival (PFS) and incidence of grade ≥3 treatment-related adverse events (TRAEs). Secondary endpoints include objective response rate and overall survival. Safety will be evaluated in all treated patients.

Discussion:

This trial will provide critical preliminary evidence on the safety, feasibility, and efficacy of integrating short-course TRT into a quadruple chemo-immuno-antiangiogenic backbone for ES-SCLC. The results are expected to inform the design of future multicenter, randomized phase III trials and potentially establish a novel multimodal paradigm for first-line management.

Trial Registration:

ClinicalTrials.gov identifier: NCT07358676. Protocol version: version 1.0, April 03, 2025.

997

项与贝莫苏拜单抗相关的新闻（医药）

2026-10-05

·医悦汇

对话大咖 | DLL3与B7-H3相继突破，冯水土教授解读小细胞肺癌治疗格局之变

编者按小细胞肺癌，长期被视为“靶点荒漠”。化疗时代结束后，免疫治疗虽带来一线突破，但复发耐药后的治疗选择始终捉襟见肘。直到2026年，DLL3与B7-H3两大靶点的临床数据相继读出，这一局面才开始松动。两个靶点的成功，不仅打破了“小细胞肺癌无可用靶点”的固有印象，更倒逼临床将DLL3、B7-H3纳入常规病理检测，推动治疗分层从模糊走向精准。在2026“海丝侨韵·肺腑同心”惠世肺癌早筛早诊及精准治疗第二届学术大会上，【医悦汇】对话大咖栏目邀请到厦门市肿瘤医院（厦门大学附属第一医院海沧院区）冯水土教授，围绕小细胞肺癌靶点成药之路、ADC与CAR-T的临床定位、免疫与ADC的协同前景，以及精准诊疗面临的核心挑战，展开深入探讨。医悦汇：从临床医生视角看，B7-H3和DLL3这两个靶点的成药之路分别走过了怎样的历程？它们的成功对于小细胞肺癌治疗格局的变革有何标志性意义？冯水土教授：DLL3靶点的研发之路非常曲折。早期DLL3 ADC药物Rova-T一度被寄予厚望，但Ⅲ期研究失败，使行业一度怀疑该靶点的价值；直至DLL3/CD3双抗塔拉妥单抗Ⅲ期研究取得阳性结果，才证实该靶点可行，属于ADC踩坑、TCE双抗破局。 B7-H3靶点则经历了单抗、双抗的多次折戟，受限于靶点本身的免疫复杂性，直至新一代ADC技术迭代，连接子与载荷不断优化，2026年多项B7-H3 ADC公布亮眼后线数据，客观缓解率实现突破，使B7-H3从科研靶点真正转化为临床可用武器，但目前均未在国内获批上市。两个靶点的成功，其标志性意义体现在两点：第一，打破小细胞肺癌“无可用靶点”的固有印象，同时为脑转移患者带来新的治疗机会，也倒逼临床将DLL3、B7-H3纳入常规病理检测，重塑全程管理思路；第二，推动治疗分层，未来可依据靶点表达状态，为复发耐药患者匹配个体化方案。但我们也应客观看到，靶点检测标准化、疗效预测生物标志物仍有待完善。与此同时，在广泛期SCLC一线治疗中，ETER701研究采用“化疗+贝莫苏拜单抗诱导，序贯贝莫苏拜单抗联合安罗替尼维持”的分段治疗策略，给出了高质量的中国人群证据，中位总生存期达到19.32个月，对比单纯化疗组延长7.43个月，被2026年版CSCO小细胞肺癌诊疗指南列为广泛期一线治疗I级推荐。该研究也确立了“免疫+抗血管生成+化疗”四药联合的一线新范式，为中国广泛期小细胞肺癌树立了新的一线治疗标杆，也为后续新型靶点药物联合提供了良好的免疫治疗基础。医悦汇：请问您如何看待ADC与CAR-T这两类不同技术路径在小细胞肺癌后线治疗中的定位差异？临床医生应如何根据患者特征在这两类创新疗法中做出选择？冯水土教授：ADC与CAR-T是两套完全不同的技术逻辑。ADC是靶向细胞毒药物，现货可用、给药方便，B7-H3 ADC已有Ⅲ期阳性证据，属于当下临床可落地的方案；其短板在于疗效依赖靶抗原表达，需警惕ILD、骨髓抑制。 CAR-T具备长期应答潜力，但实体瘤瓶颈尚未解决，小细胞肺癌CAR-T仍处于Ⅰ期临床探索阶段，需经历细胞采集、体外修饰、清淋预处理、回输的完整流程，制备周期长，暂无获批临床适应证，目前仅限于临床试验。在临床选择上，首先应进行靶点评估：DLL3、B7-H3表达水平是重要参考；其次评估ECOG体能状态与脏器功能。对于体能状态好、靶标阳性、多线治疗失败的患者，优先考虑ADC。CAR-T目前更多集中于临床试验，适合愿意参与研究、经过充分筛选后ECOG良好、淋巴细胞储备佳、所有标准方案失败的患者，尚不能常规用于真实世界。此外，我们也在思考，ADC是否可以与贝莫苏拜单抗这类PD-L1抑制剂开展联合：ADC杀伤肿瘤释放肿瘤抗原，PD-L1解除免疫抑制，理论上具备协同潜力，值得开展临床探索。医悦汇：您如何看待免疫治疗与ADC药物在小细胞肺癌不同治疗阶段中的协同潜力？冯水土教授：机制上，二者具备协同基础：ADC杀伤肿瘤可诱导免疫原性细胞死亡，释放肿瘤新抗原，将冷肿瘤转为热肿瘤，免疫药物则放大抗肿瘤免疫。但小细胞肺癌不同疾病阶段，肿瘤负荷、肿瘤微环境、免疫状态差异巨大，免疫与ADC的协同逻辑也各不相同。第一，局限期SCLC根治后巩固阶段：目前标准为度伐利尤单抗巩固，但半数患者仍远处复发。现阶段ADC并不适合直接用于局限期巩固，局限期目标是追求长期治愈，ADC毒性特征尚不适合长期维持。未来可以探索：如果根治后出现微小残留、高复发风险人群，评估ADC联合免疫的研究价值。第二，广泛期SCLC一线：当前标准已包含PD-L1抑制剂联合化疗，前述四药方案已实现优秀总生存数据。随着2026年ADC、塔拉妥单抗数据落地，未来1-2年，广泛期一线的精准联合方案将出现新的治疗准则。一线直接将ADC纳入是联合探索最热门的场景，有望克服一线免疫化疗耐药，但需谨慎平衡疗效叠加与毒性叠加。未来的研究方向不是简单堆砌药物，而是筛选亚组：例如肿瘤负荷高、神经内分泌亚型显著的患者，探索在免疫+化疗基础之上联合ADC，但必须做好安全性管控。第三，复发后线阶段是免疫与ADC协同最有前景的场景。很多患者一线免疫治疗之后耐药，肿瘤微环境高度抑制。ADC有望将“冷肿瘤”转化为“热肿瘤”，重新恢复对免疫药物的敏感性。但此处仍有许多待解答的问题：联合顺序，是ADC与免疫同步，还是ADC序贯免疫；哪些生物标志物可以筛选获益人群；联合之后不良反应如何管理，均需要更多真实世界与临床研究去回答。总体来看，ADC联合免疫虽有理论优势，但全部处于临床研究阶段，不能替代现有标准方案。医悦汇：在新药密集涌现的背景下，您认为当前小细胞肺癌精准诊疗领域最大的挑战是什么？冯水土教授：目前存在的挑战有很多，例如生物标志物体系不完善、真实世界与临床试验之间存在鸿沟、治疗决策越来越复杂、治疗排兵布阵没有标准答案、药物可及性问题等。最大挑战是小细胞肺癌本身高度的时空异质性：原发灶、转移灶靶点表达不一致，经过化疗、免疫治疗压力后还会发生抗原丢失，单次活检难以代表全身肿瘤状态，造成靶点阳性但疗效不佳；同时DLL3、B7-H3缺乏统一检测判读标准，缺少成熟伴随诊断，筛选真正获益患者难度大；如何精准筛选获益人群，是当前核心难题。面向未来，一方面要继续鼓励国产创新药研发，另一方面，要推进检测标准化、开展更多中国人群真实世界研究，把临床试验的优秀数据真正转化为普通患者实实在在的生存获益。写在后面小细胞肺癌的精准治疗，正在从“无靶可打”走向“有靶可测、有药可选”的新阶段。但方向明确不等于路径平坦。靶点检测标准化、疗效预测生物标志物、ADC与免疫的最佳联合顺序、CAR-T在实体瘤中的瓶颈突破，以及小细胞肺癌高度时空异质性带来的“靶点阳性却疗效不佳”难题，仍需大量真实世界研究与临床探索去回答。正如冯水土教授所言，当前最大的挑战是如何精准筛选获益人群，而解决这一难题，既需要国产创新药的持续研发，也需要检测标准化与中国人群真实世界研究的协同推进。从“有药可用”到“用得精准”，小细胞肺癌的精准诊疗仍有长路要走。但靶点成药之门的开启，已经让这个曾经被边缘化的瘤种，站到了创新治疗舞台的中央。专家简介冯水土三级主任医师、教授厦门市肿瘤医院（厦门大学附属第一医院海沧院区）副院长 ▶ 中国抗癌协会肿瘤整体评估专业委员会副主任委员 ▶ 中国医药教育协会腹部肿瘤医学综合康复分会副主任委员 ▶ 福建省抗癌协会多原发和不明原发肿瘤专业委员会副主任委员 ▶ 厦门市医师协会医学科学普及分会会长 ▶ 厦门市医学会肿瘤学分会副主任委员 ▶ 第一届福建省预防医学会预防与转化专业委员会副主委 ▶ 福建省中医药学会常务理事、乳腺病分会常委 ▶ 第二届厦门市中西医结合学会肿瘤学分会副主委 ▶ 白求恩式好医生（全国第五届） ▶ 福建青年五四奖章获得者 ▶ 福建省闽江科学传播学者 ▶ 厦门市劳模 ▶ 厦门市高层次人才（B级） ▶ 厦门市青年创新人才 ▶ 厦门市“十佳”青年医生 ▶ 海沧区领军人才 ▶ 海沧区科协常委、海沧区人大代表免责声明：本账号分享的内容仅为健康信息科普，不构成任何医疗建议。个人健康问题，请务必咨询执业医师。编辑 | 晓娟视频 | 粘洞审核 | 佼娇鹏哥审校 | 冯水土版权声明：本文版权归医悦汇所有，欢迎转发分享！其他任何媒体如需转载或引用本网版权所有内容，须获得授权，且在醒目位置处注明 “ 转自：医悦汇 ”。

2026-10-03

·雪儿学堂

【2026ESMO】胰腺癌篇章新进展全局观

“ KRAS 从「不可成药」到制药工业最拥挤的赛道，围手术期抑制剂与治疗性疫苗同时推进，胰腺癌的治疗逻辑正在被重写。 —— ESMO 2026 消化道肿瘤摘要解读系列胰腺癌是消化道肿瘤中预后最差的瘤种，也是本届 ESMO 投入最集中的领域之一。我们提取到胰腺癌相关摘要 138 条，体量在六大瘤种中位列第二，其中包含 2 场口头报告、多项 III 期研究和正在进行的一线随机试验。本文把 138 条摘要归为四条战线：KRAS 靶向、免疫与治疗性疫苗、局部治疗强化、化疗策略与真实世界证据，文末附完整清单。 📌 本文看点 01 KRAS G12D 的临床化路径 02 4 项 LBA 密集披露 03 围手术期与局部强化 01 DATA SCAN数据概览：138 条摘要，四大方向同时推进 138 条摘要的形式分布以 Poster 与 ePoster 为主，但看点高度集中在少数重磅研究上：2 场口头报告、4 项 LBA、多项一线 III 期与围手术期研究。中国研究者贡献 30 条摘要，覆盖 KRAS G12D 靶向、真实世界数据与局部治疗。从研究类型看，胰腺癌的方向分化特别明显——一类研究解决「用什么药」，一类解决「什么时候用、联合什么」。 138 胰腺癌相关摘要（条） 2 / 7 口头报告 / 进行中试验 33 中国讲者摘要（条） 129 Poster 与 ePoster 一句话结论：胰腺癌的新药竞争已从化疗骨架的排列组合，转向KRAS 精准靶向与免疫治疗性疫苗。 02 HIGHLIGHTS重磅研究解读本届胰腺癌的口头报告与 4 项 LBA 覆盖了靶向、免疫、局部强化与化疗策略四条主线。 CASE 3137RORapid Oral 新型口服KRAS G12D抑制剂INCB161734联合化疗治疗晚期/转移性胰腺导管腺癌（PDAC）患者的安全性与疗效 Safety and Efficacy of INCB161734, a Novel Oral KRAS G12D Inhibitor, in Combination with Chemotherapy in Patients (pts) with Advanced/Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) 讲者：Antoine Hollebecque (Villejuif, France) 新型口服 KRAS G12D 抑制剂 INCB161734 联合化疗的早期数据，是本届口头报告中最受关注的新机制之一。G12D 是胰腺癌最主要的 KRAS 突变亚型，口服小分子的可及性优势，将直接影响这一赛道的落地速度。 CASE LBA82LBA · 优选论文 RAS(ON) 多选择性抑制剂 daraxonrasib 对比化疗用于经治转移性胰腺导管腺癌：III 期 RASolute 302 研究补充亚组分析 Daraxonrasib, a RAS(ON) multi-selective inhibitor vs chemotherapy in previously treated metastatic pancreatic adenocarcinoma: additional subgroup analyses from the Ph3 RASolute 302 study 讲者：Zev A. Wainberg｜洛杉矶，美国 RASolute 302 是 KRAS 抑制剂首次在胰腺癌经治人群中以 III 期形式呈现，本届公布补充亚组分析。「多选择性 RAS(ON) 抑制剂」意味着它不再局限于单一突变亚型，这对突变谱分散的胰腺癌尤为关键。 CASE LBA85LBA · 快速口头报告 HRS-4642 联合化疗±阿得贝利单抗用于 KRAS G12D 突变胰腺癌围手术期治疗：II 期研究初步结果 HRS-4642 plus chemotherapy ± adebrelimab as perioperative therapy in KRAS G12D-mutant pancreatic cancer: preliminary results of a phase 2 study 讲者：沈柏用｜上海交通大学医学院附属瑞金医院国产 KRAS G12D 抑制剂 HRS-4642 直接把适应场景前移到围手术期，并叠加 PD-L1 抗体。这类「靶向+免疫+化疗」的围手术期组合，是本届胰腺癌最具想象力的设计之一。 CASE LBA83LBA · 优选论文七价 mKRAS 特异性淋巴结靶向两亲性免疫治疗对比观察用于已切除胰腺导管腺癌：AMPLIFY-7P 随机 II 期研究 Seven-Valent mKRAS-specific lymph node targeted amphiphile immunotherapy versus observation in resected pancreatic ductal adenocarcinoma: the AMPLIFY-7P randomized phase 2 study 讲者：Eileen M. O’Reilly｜纽约，美国 AMPLIFY-7P 用七价 KRAS 特异性治疗性疫苗挑战术后观察，是免疫治疗在胰腺癌最艰难场景（微小残留病灶）中的一次正面尝试。淋巴结靶向递送技术能否突破胰腺癌的低免疫原性，值得跟踪。 CASE 3136RORapid Oral mFOLFIRINOX±SBRT治疗高危、交界可切除或局部晚期胰腺癌的随机II期研究：AGITG MASTERPLAN试验结果 Randomised Phase II study of mFOLFIRINOX±SBRT in patients with high risk, borderline resectable or locally advanced pancreatic cancer: Results of the AGITG MASTERPLAN trial 讲者：Andrew Oar (Southport, Australia) AGITG MASTERPLAN 研究评估 mFOLFIRINOX±SBRT 用于高危、边缘可切除或局部晚期胰腺癌。SBRT 的加入能否提高可切除转化率，是这项随机 II 期最有临床价值的问题。 CASE LBA84LBA · 快速口头报告一线治疗失败晚期胰腺癌，双药对比单药治疗的随机、多中心、开放标签、双臂 III 期研究（Panc-SELECT——吉西他滨队列） A randomized, multicenter, open-label, double-arm, phase III study of doublet vs monotherapy in advanced pancreatic cancer patients who have failed first-line therapy (Panc-SELECT — gemcitabine arms) 讲者：Prabhat G. Bhargava｜孟买，印度 Panc-SELECT 关注一个很实际的问题：一线失败后，二线到底该用双药还是单药。在体能状态普遍下降的胰腺癌二线人群中，这类研究直接决定临床路径。 CASE 3190TiPTrial in Progress poster setidegrasib联合mFOLFIRINOX或NALIRIFOX一线治疗KRAS G12D突变转移性胰腺导管腺癌（PDAC）的3期双盲随机试验：进行中的试验 A Phase 3, double-blind, randomized trial of setidegrasib + mFOLFIRINOX or NALIRIFOX as first-line treatment for patients with metastatic pancreatic ductal adenocarcinoma (PDAC) harboring KRAS G12D mutations: Trial in progress 讲者：Teresa Macarulla Mercade (Barcelona, Spain) setidegrasib 联合 mFOLFIRINOX 或 NALIRIFOX 一线治疗 KRAS G12D 突变胰腺癌的 III 期双盲随机研究。KRAS G12D 抑制剂正式进入一线III期梯队，这是本届胰腺癌在研管线最重要的信号。 CASE 3147PPoster 多药联合化疗对比吉西他滨治疗体弱或老年晚期胰腺癌（MaGPiE）：一项III期随机试验的中期安全性分析 Multi-agent chemotherapy versus gemcitabine in frail or elderly advanced pancreatic cancer (MaGPiE), interim safety analysis of a phase III randomised trial 讲者：Vikas S. Ostwal (Mumbai, India) MaGPiE III 期中期安全性分析：多药联合化疗对比吉西他滨用于体弱或老年晚期胰腺癌。在体能状态受限人群中寻找「减毒而不减效」的方案，比在优势人群中做加法更有现实意义。 03 TRENDS研究方向盘点四条战线各自都有明确的问题清单。 KRAS 靶向：从单亚型到多选择性 INCB161734（3137RO）、daraxonrasib（LBA82）、setidegrasib（3190TiP）、HRS-4642（LBA85）构成完整梯队。从后线到一线、从单药到联合化疗，KRAS 抑制剂的临床化路径已经清晰，接下来比拼的是疗效深度与耐药管理。免疫与治疗性疫苗：从小样本到随机对照 mKRAS 七价疫苗（LBA83）、atebimetinib 联合化疗的一线 III 期（3189TiP）、以及多项免疫联合探索，共同回答「胰腺癌的冷肿瘤属性能否被打破」。局部治疗强化：可切除边界的再定义 mFOLFIRINOX±SBRT（3136RO）与多项新辅助/转化研究，试图用放疗与更强化疗把边缘可切除人群推向 R0 切除。化疗策略与真实世界证据：被低估的部分 Panc-SELECT（LBA84）解决二线双药与单药之争，MaGPiE（3147P）关注老年体弱人群，奥拉帕利维持治疗的真实世界评价（3216eP）则补充了 BRCA 突变人群在临床实践中的表现。 04 FULL LIST完整摘要清单以下为本届 ESMO 胰腺癌相关全部 138 条摘要（中国讲者 30 条），按摘要编号排序。中文题目为 AI 辅助翻译，仅供检索参考。摘要编号作者（讲者）题目（中文 / 英文） 2902P Chao Li (Beijing, China) 基于VHH的抗CLDN18.2 CAR-T疗法IMC002治疗胃/胃食管结合部癌和胰腺癌的I/IIa期试验：持久的缓解与良好的安全性Durable responses with a favorable safety profile in a phase I/IIa trial of IMC002, a VHH-based anti-CLDN18.2 CAR-T therapy for gastric/gastroesophageal junction and pancreatic cancers 3012eP Stephen L. Slocum (Daejeon, Republic of Korea) LCB02A：一种靶向Claudin 18.2的ADC，用于治疗胃癌、胰腺癌及其他Claudin 18.2表达肿瘤LCB02A, a Claudin 18.2-directed ADC, for the Treatment of Gastric, Pancreatic, and Other Claudin 18.2-Expressing Cancers 3136RO Andrew Oar (Southport, Australia) mFOLFIRINOX±SBRT治疗高危、交界可切除或局部晚期胰腺癌的随机II期研究：AGITG MASTERPLAN试验结果Randomised Phase II study of mFOLFIRINOX±SBRT in patients with high risk, borderline resectable or locally advanced pancreatic cancer: Results of the AGITG MASTERPLAN trial 3137RO Antoine Hollebecque (Villejuif, France) 新型口服KRAS G12D抑制剂INCB161734联合化疗治疗晚期/转移性胰腺导管腺癌（PDAC）患者的安全性与疗效Safety and Efficacy of INCB161734, a Novel Oral KRAS G12D Inhibitor, in Combination with Chemotherapy in Patients (pts) with Advanced/Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) 3138P Shinji Itoh (Fukuoka, Japan) 使用基于全基因组测序的ctDNA检测可切除胰腺癌的分子残留病灶（MRD）：MONSTAR-SCREEN-3的初步发现Molecular Residual Disease Detection for Resectable Pancreas Cancer Using a whole-genome sequencing-based ctDNA assay: Initial findings from the MONSTAR-SCREEN-3 3139P Casper W.F. Van Eijck (Rotterdam, Netherlands) 血浆ctDNA甲基化单倍型图谱作为胰腺导管腺癌FOLFIRINOX方案疗效的预测性生物标志物Plasma ctDNA methylation haplotype profiling as a predictive biomarker for FOLFIRINOX response in pancreatic ductal adenocarcinoma 3140P Dan Zhao (Houston, United States of America) KRAS Q61突变胃肠道恶性肿瘤的等位基因特异性特征及其与胰腺癌临床结局和转录组特征的关系Allele Specific Characteristics of KRASQ61 Mutated Gastrointestinal Malignancies with Clinical Outcomes and Transcriptomic Features in Pancreatic Cancer 3141P Ashish Sharma (New Haven, United States of America) 最大PDAC基因组数据集中种族和民族数据的完全缺失阻碍了对新兴等位基因剂量生物标志物的公平性相关验证：一项数据治理审计Complete absence of race and ethnicity data in the largest PDAC genomic dataset prevents equity-relevant validation of emerging allele dosage biomarkers: a data governance audit 3142P Ashish Sharma (New Haven, United States of America) KRAS等位基因身份和肿瘤突变负荷（TMB）无法区分胰腺导管腺癌中的超常应答者与快速进展者：一项质疑等位基因决定论的阶段匹配极端表型分析KRAS allele identity and tumour mutational burden do not differentiate exceptional responders from rapid progressors in pancreatic ductal adenocarcinoma: a stage-matched extreme-phenotype analysis questioning allele determinism 3143P Christoph Gerdes (Toronto, Canada) 胰腺癌的转录组学重新分类揭示新的分子亚型Transcriptomic Reclassification of Pancreatic Cancer Uncovers Novel Molecular Subtypes 3144P Franck MONNIEN (Besançon, France) 基质HSP47和膜β-catenin作为胰腺导管腺癌辅助化疗获益的预后和预测性生物标志物：模型构建与独立验证Stromal HSP47 and membranous β-catenin as prognostic and predictive biomarkers of adjuvant chemotherapy benefit in pancreatic ductal adenocarcinoma: development and independent validation 3145P Dongsheng Zhang (Guangzhou, China) 维迪西妥单抗（Disitamab Vedotin）治疗HER2表达局部晚期或转移性胰腺癌：一项前瞻性、单臂、II期临床试验Disitamab Vedotin in HER2-Expressing Locally Advanced or Metastatic Pancreatic Cancer: A Prospective, Single-Arm, Phase II Clinical Trial 3146P Vincent Chung (Duarte, United States of America) 仑伐替尼-帕博利珠单抗维持治疗晚期胰腺导管腺癌（PDAC）：II期试验（NCT04887805）结果及免疫相关标志物Lenvatinib-pembrolizumab maintenance therapy in advanced pancreatic ductal adenocarcinoma (PDAC): Phase II trial (NCT04887805) results and immunological correlatives 3147P Vikas S. Ostwal (Mumbai, India) 多药联合化疗对比吉西他滨治疗体弱或老年晚期胰腺癌（MaGPiE）：一项III期随机试验的中期安全性分析Multi-agent chemotherapy versus gemcitabine in frail or elderly advanced pancreatic cancer (MaGPiE), interim safety analysis of a phase III randomised trial 3148P Shinichiro Takahashi (Makinohara, Japan) 新辅助吉西他滨联合白蛋白结合型紫杉醇对比基于S-1的放化疗治疗交界可切除胰腺癌的II/III期试验5年更新（GABARNANCE）5-year update of the phase II/III trial of neoadjuvant gemcitabine plus nab-paclitaxel versus S-1-based chemoradiotherapy for borderline resectable pancreatic cancer (GABARNANCE) 3149P Alexander I. Spira (Fairfax, United States of America) vopimetostat联合daraxonrasib或zoldonrasib治疗MTAP缺失、RAS突变（MTAPdel/RASmut）转移性PDAC和NSCLC患者的1/2期研究A Phase 1/2 study of vopimetostat in combination with daraxonrasib or zoldonrasib in patients with MTAP deleted RAS mutated (MTAPdel/RASmut) metastatic PDAC and NSCLC 3150P Dan Cao (Chengdu, China) HRS-4642联合尼妥珠单抗（nimotuzumab）治疗KRAS G12D突变晚期胰腺导管腺癌患者的Ib/II期研究A Phase Ib/II Study of HRS-4642 plus Nimotuzumab in Patients with KRAS G12D-Mutant Advanced Pancreatic Ductal Adenocarcinoma 3151P David J. Pinato (London, United Kingdom) 辅助intismeran autogene联合FOLFIRINOX治疗可切除胰腺导管腺癌：一项I期研究结果Adjuvant intismeran autogene plus FOLFIRINOX in resectable pancreatic ductal adenocarcinoma: results from a phase I study 3152P Teresa Macarulla Mercade (Barcelona, Spain) 与Ibrilatazar联合FOLFIRINOX治疗后转移性胰腺癌结局改善相关的临床相关亚群：来自PanC-ASAP试验的探索性分析Clinically Relevant Subpopulations Associated with Improved Outcomes Following Ibrilatazar Plus FOLFIRINOX in Metastatic Pancreatic Cancer: An Exploratory Analyses from the PanC-ASAP Trial 3153P Salomon M. Stemmer (Petah Tikva, Israel) Namodenoson在晚期胰腺腺癌中实现持久的疾病稳定：一项2a期研究结果Durable Disease Stabilization with Namodenoson in Advanced Pancreatic Adenocarcinoma: Results from a Phase 2a Study 3154P Mette H. Nissen (Herlev, Denmark) 晚期胰腺癌的早期专科姑息治疗（EarlyCarePan）：一项丹麦全国性随机试验Early specialized palliative care in advanced pancreatic cancer (EarlyCarePan): a nationwide Danish randomized trial 3155P Rui Liu (Tianjin, China) QL1706联合西达本胺（chidamide）、白蛋白结合型紫杉醇和吉西他滨一线治疗转移性胰腺癌的疗效与安全性：一项前瞻性、单臂临床试验Efficacy and Safety of QL1706 Combined with Chidamide, Nab-Paclitaxel, and Gemcitabine as First-Line Treatment for Metastatic Pancreatic Cancer: A Prospective, Single-Arm Clinical Trial 3156P Shukui Qin (Nanjing, China) 索凡替尼（surufatinib）联合卡瑞利珠单抗、白蛋白结合型紫杉醇和吉西他滨一线治疗转移性胰腺癌的最终2期分析Final phase 2 analysis of surufatinib plus camrelizumab, nab-paclitaxel and gemcitabine in first-line metastatic pancreatic cancer 3157P Wen-Quan Wang (Shanghai, China) HRS-4642联合双免疫治疗和化疗治疗晚期胰腺癌：一项II期研究第1臂的初步结果HRS-4642 with dual immunotherapy and chemotherapy for advanced pancreatic cancer: Preliminary results from Arm 1 of a phase II study 3158P Huizi Sha (Nanjing, China) 派安普利单抗、安罗替尼与AG化疗联合作为转移性胰腺癌一线方案：一项多中心、随机对照试验（RCT-PAAG）Integrated Penpulimab, Anlotinib and AG Chemotherapy as First-Line Regimen for Metastatic Pancreatic Cancer: A Multi-Centered, Randomized Controlled Trial (RCT-PAAG) 3159P Xiang Kong (Nanjing, China) 脂质体伊立替康（nal-IRI）/5-FU/LV、贝莫苏拜单抗和安罗替尼联合（伴或不伴SBRT）二线治疗转移性胰腺癌：一项II期双队列研究Integrated nal-IRI/5-FU/LV, benmelstobart, and anlotinib with or without SBRT for second-line metastatic pancreatic cancer: A phase II dual-cohort study 3160P Songul Kucukcelebi (Rotterdam, Netherlands) 已切除胰腺癌接受基于树突状细胞的辅助免疫治疗后的长期临床结局和免疫谱分析：REACtiVe-1试验更新结果Long-term clinical outcomes and immune profiling after adjuvant dendritic cell-based immunotherapy in resected pancreatic cancer: updated REACtiVe-1 trial results. 3161P Huikai Li (Tianjin, China) 新辅助依沃西单抗（ivonescimab）联合吉西他滨/白蛋白结合型紫杉醇治疗交界可切除胰腺癌：一项前瞻性单臂II期试验Neoadjuvant ivonescimab plus gemcitabine/nab-paclitaxel for borderline resectable pancreatic cancer: a prospective single-arm phase II trial 3162P Haochen Tang (Nanjing, China) 尼妥珠单抗联合标准辅助化疗用于胰腺癌根治性切除术后：一项前瞻性单臂、双队列II期研究的初步结果Nimotuzumab plus standard adjuvant chemotherapy after curative resection for pancreatic cancer: preliminary results of a prospective single-arm, two-cohort phase II study 3163P Letizia Procaccio (Padua, Italy) PAXG方案对比(m)FOLFIRINOX一线治疗转移性胰腺癌患者：一项多中心目标试验模拟研究PAXG versus (m)FOLFIRINOX as first-line therapy for patients with metastatic pancreatic cancer: a multicenter, target trial emulation study 3164P Janet Graham (Glasgow, United Kingdom) PRIMUS-001：FOLFOX-A（FOLFOX/白蛋白结合型紫杉醇）对比AG（白蛋白结合型紫杉醇/吉西他滨）治疗转移性胰腺癌患者的适应性2期研究，并含生物标志物评估PRIMUS-001: An adaptive phase 2 study of FOLFOX-A (FOLFOX/nab-paclitaxel) versus AG (nab-paclitaxel/gemcitabine) in patients with metastatic pancreatic cancer, with biomarker evaluation 3165P Baiyong Shen (Shanghai, China) 围手术期HRS-4642、化疗和阿得贝利单抗治疗KRAS G12D突变胰腺癌：II期初步结果Perioperative HRS-4642, Chemotherapy, and Adebrelimab in KRAS G12D-Mutant Pancreatic Cancer: Preliminary Phase 2 Results 3166P Marc Hilmi (New York, United States of America) 表达骨膜蛋白（POSTN）的胰腺癌相关成纤维细胞（CAFs）定义了与肿瘤侵袭性和治疗反应相关的独特生态位：来自PRODIGE 24试验的证据Periostin (POSTN)-expressing pancreatic cancer-associated fibroblasts (CAFs) define a distinct niche associated with tumor aggressiveness and therapeutic response: evidence from PRODIGE 24 trial 3167P Laura K. Kjær (Herlev, Denmark) 纳武利尤单抗联合伊匹木单抗、TGFβ-15肽疫苗和立体定向体部放疗治疗难治性胰腺癌的I期研究（CheckVAC）Phase I study of nivolumab with ipilimumab combined with TGFβ-15 peptide vaccine and stereotactic body radiotherapy for refractory pancreatic cancer (CheckVAC) 3168P Jialin Li (Shanghai, China) 六周诱导吉西他滨联合白蛋白结合型紫杉醇（AG）后序贯索凡替尼联合AG或单用AG一线治疗局部晚期或转移性胰腺导管腺癌（mPDAC）：一项单中心、双队列II期研究Six Weeks of Induction Gemcitabine Plus Nab Paclitaxel (AG) Followed by Sequential Surufatinib Plus AG or AG alone as First Line Therapy for Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC): A Single Center, Two Cohort, Phase II Study 3169P Xianjun Yu (Shanghai, China) TQB2868联合白蛋白结合型紫杉醇/吉西他滨±安罗替尼一线治疗转移性胰腺导管腺癌：一项前瞻性多中心双队列II期研究TQB2868 Plus Nab-Paclitaxel/Gemcitabine ± Anlotinib as First-Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma: A Prospective Multicenter Two-Cohort Phase II Study 3170P Noha F. Rashad (Suez, Egypt) OligoPanc共识定义的寡转移胰腺导管腺癌作为预后分层工具对比其他定义标准的价值：一项回顾性验证研究（GI Characterize-PANC-1）The value of OligoPanc consensus definition of Oligometastatic pancreatic ductal adenocarcinoma as a prognostic stratification tool compared to alternative defining criteria: A retrospective validation study (GI Characterize-PANC-1). 3171P Guillaume Ulmann (Saint-Ouen-sur-Seine, France) 已切除胰腺癌营养不良的经济负担：一项全国性卫生经济学研究Economic Burden of Malnutrition in Resected Pancreatic Cancer: A Nationwide Health Economic Study 3172P Rafael Alvarez Gallego (Madrid, Spain) 接受脂质体伊立替康（nal-IRI）治疗的转移性胰腺导管腺癌（mPDAC）患者的长期生存：NALLONG研究与西班牙队列（NALLONG2）的汇总分析Long-term survival in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan (nal-IRI): a pooled analysis of the NALLONG study and a Spanish cohort (NALLONG2) 3173P Ashish Sharma (New Haven, United States of America) KRAS突变拷贝增加与胰腺导管腺癌的转移表现共分离：1157例注释患者中等位基因剂量生物学的新拓展KRAS mutant copy gain co-segregates with metastatic presentation in pancreatic ductal adenocarcinoma: a novel extension of allele dosage biology in 1,157 annotated patients 3174P Antonio Pea (Verona, Italy) 基于病理学的导管内肿瘤相关胰腺癌复发风险模型，用于指导辅助治疗A Pathology-Based Recurrence Risk Model for Intraductal Neoplasm–Associated Pancreatic Carcinoma to Inform Adjuvant Therapy 3175P Giulia Orsi (Milan, Italy) 导管内乳头状黏液性肿瘤（IPMN）来源的胰腺导管腺癌：诊断和治疗意义Intraductal papillary mucinous neoplasm (IPMN)-derived Pancreatic Ductal Adenocarcinoma: diagnostic and therapeutic implications 3176P Minami Nomura (Minato-ku, Japan) SMAD4状态在不可切除胰腺导管腺癌中依赖背景的预后影响Context-dependent prognostic impact of SMAD4 status in unresected pancreatic ductal adenocarcinoma 3177P Marc Hilmi (New York, United States of America) 致病性ATM缺失定义了预后更佳、肝脏趋向性降低且具有独特KRAS-肿瘤微环境（TME）生物学的胰腺癌（PC）Pathogenic ATM loss defines pancreatic cancer (PC) with better prognosis, reduced liver tropism and distinct KRAS-tumor microenvironment (TME) biology 3178P Fieke E. Froeling (Glasgow, United Kingdom) Precision-Panc：英国胰腺癌治疗研发平台的经验与启示（NCT04161417）Precision-Panc: UK therapeutic development platform for pancreatic cancer, experience and lessons learnt (NCT04161417) 3179P Kamal Al-rabi (Amman, Jordan) PDAC的比较基因组图谱：来自中东和全球队列的见解Comparative Genomic Landscape of PDAC: Insights from Middle Eastern and Global Cohorts 3180P Aina De Torner Vidal (Barcelona, Spain) 揭示早发性胰腺癌：来自真实世界队列的临床、分子和治疗见解Unveiling Early-Onset Pancreatic Cancer: clinical, molecular and therapeutic insights from a real-world cohort 3181P Erwan Vo Quang (Paris, France) 免疫检查点抑制剂在MSI-H/dMMR晚期胰腺腺癌中的疗效：一项国际队列的更新分析Efficacy of immune checkpoint inhibitors in MSI-H/dMMR advanced pancreatic adenocarcinoma: updated analysis of an international cohort 3182P Kreina S. Vega Cano (Barcelona, Spain) 根据化疗顺序划分的晚期胰腺导管腺癌（PDAC）真实世界结局Real-world outcomes according to chemotherapy sequencing in advanced pancreatic ductal adenocarcinoma (PDAC) 3183P Morten Karsdal (Herlev, Denmark) 癌症相关成纤维细胞（CAFs）和肿瘤纤维化的液体活检用于评估接受纳武利尤单抗/放疗±伊匹木单抗或吉西他滨/白蛋白结合型紫杉醇±托珠单抗（tocilizumab）治疗的胰腺癌患者的疗效和生存Liquid biopsy of cancer-associated fibroblasts (CAFs) and tumor fibrosis for assessment of response and survival in pancreas cancer patients treated with Nivolumab/radiotherapy ± Ipilimumab or Gemcitabine/Nab-Paclitaxel ± Tocilizumab 3184P Daniel A. King (Lake Success, United States of America) 抗PAUF单克隆抗体PBP1510治疗转移性胰腺腺癌的安全性与疗效Safety and Efficacy of PBP1510, an Anti-PAUF Monoclonal Antibody, in Metastatic Pancreatic Adenocarcinoma 3185P Katherine G. Roth (Duarte, United States of America) PARP抑制剂和铂类化疗改善胰腺腺癌生存，且不依赖于HRD状态PARP inhibitors and Platinum Chemotherapy Improve Survival in Pancreatic Adenocarcinoma Independent of HRD Status 3186TiP Cindy Neuzillet (Boulogne-Billancourt, France) 优化一线NALIRIFOX方案并探索微生物群在胰腺癌二线治疗中的作用：PRODIGE 105 GERCOR PANORAMIX研究Optimizing 1st-line NALIRIFOX and Exploring the Role of Microbiota in 2nd-line Pancreatic Cancer Treatment: The PRODIGE 105 GERCOR PANORAMIX study 3187TiP Maria Pia Morelli (Houston, United States of America) 一项评估Navlimetostat（BMS-986504）联合化疗治疗可切除/交界可切除（队列1）、局部晚期不可切除（队列2）和转移性（队列3）MTAP缺失胰腺癌的II期研究A Phase II Study Evaluating Navlimetostat (BMS-986504) and chemotherapy in resectable/borderline resectable (cohort 1), locally advanced, unresectable (cohort 2), and metastatic (cohort 3) MTAP-deleted Pancreatic Cancer. 3188TiP Do-Youn Oh (Seoul, Republic of Korea) 靶向EphA2的Bicycle药物偶联物（BDC）Nuzefatide Pevedotin治疗转移性胰腺导管腺癌（PDAC）患者的2期研究Phase 2 Study of Nuzefatide Pevedotin, an EphA2-targeting Bicycle Drug Conjugate (BDC), in Patients (Pts) With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) 3189TiP Eileen M. O’Reilly (New York, United States of America) 进行中试验——MAPKeeper-301：Atebimetinib联合改良吉西他滨和白蛋白结合型紫杉醇方案对比标准吉西他滨和白蛋白结合型紫杉醇治疗转移性胰腺导管腺癌患者的3期随机、开放标签研究Trial In Progress- MAPKeeper-301: A Phase 3 Randomized, Open-Label Study of Atebimetinib in Combination with the Modified Gemcitabine and nab-Paclitaxel Regimen Versus Standard Gemcitabine and nab-Paclitaxel for Treatment of Patients with Metastatic Pancreatic Ductal Adenocarcinoma 3190TiP Teresa Macarulla Mercade (Barcelona, Spain) setidegrasib联合mFOLFIRINOX或NALIRIFOX一线治疗KRAS G12D突变转移性胰腺导管腺癌（PDAC）的3期双盲随机试验：进行中的试验A Phase 3, double-blind, randomized trial of setidegrasib + mFOLFIRINOX or NALIRIFOX as first-line treatment for patients with metastatic pancreatic ductal adenocarcinoma (PDAC) harboring KRAS G12D mutations: Trial in progress 3191eP Shuai Xiang (Beijing, China) 蛋白质组学驱动的机器学习策略实现新发糖尿病患者胰腺癌的早期检测Proteomic-driven machine learning strategy enables early detection of pancreatic cancer in new-onset diabetes 3192eP Miguel García-Bartolomé (Valencia, Spain) 术后TAV16 ctDNA检测分子残留病灶并预测胰腺癌切除术后复发Postoperative TAV16 ctDNA detects molecular residual disease and predicts relapse after pancreatic cancer resection 3193eP Santiago Sucre (Miami, United States of America) Avutometinib联合defactinib（AvDf）联合或不联合吉西他滨和白蛋白紫杉醇（GnP）治疗既往经治的KRAS突变胰腺导管腺癌（PDAC）患者Avutometinib plus defactinib (AvDf) with or without gemcitabine and nab-Paclitaxel (GnP) in previously treated patients with pancreatic ductal adenocarcinoma (PDAC) harboring KRAS mutations 3194eP Maroua Boujemaa (Tunis, Tunisia) 突尼斯胰腺癌的临床与胚系基因组特征：基因组稳定性及表观遗传通路参与的证据Clinical and Germline Genomic Characterization of Pancreatic Cancer in Tunisia: Evidence for Genome Stability and Epigenetic Pathway Involvement 3195eP Anke Onnekink (Leiden, Netherlands) 携带CDKN2A/p16胚系致病变异个体的胰腺导管腺癌基因组特征Genomic Characterization of Pancreatic Ductal Adenocarcinomas in Individuals with a Germline CDKN2A/p16 Pathogenic Variant 3196eP Carmen Cobos Lama (Madrid, Spain) 杂交捕获二代测序作为PDAC胚系基因组变异筛查工具的应用Hybrid-capture next-generation sequencing as a screening tool for germline genomic alterations in PDAC 3197eP Yung-yeh Su (Tainan City, Taiwan) 胰腺导管腺癌中KRAS突变特异性信号传导与转录程序KRAS Mutation-Specific Signalling and Transcriptomic Programmes in Pancreatic Ductal Adenocarcinoma 3198eP Fengwei Xu (Hang Zhou, China) 靶向PD-L1的ADCplex递送泛KRAS分子胶和伊立替康，在临床前胰腺癌模型中显示出强效抗肿瘤活性且毒性降低PD-L1–Targeted ADCplex Delivering a Pan-KRAS Molecular Glue and Irinotecan Demonstrates Potent Antitumor Activity With Reduced Toxicity in Preclinical Pancreatic Cancer Models 3199eP Shiwei Guo (Shanghai, China) PDAClassify：一种基于甲基化的分类器，用于胰腺导管腺癌的无创分子分型PDAClassify: a methylation-based classifier for non-invasive molecular subtyping of pancreatic ductal adenocarcinoma 3200eP Haripriya Andanamala (Oklahoma City, United States of America) SMAD4和HRD突变决定局限期胰腺癌新辅助化疗的不同应答SMAD4 and HRD Mutations Dictate Divergent Neoadjuvant Chemotherapy Responses in Localized Pancreatic Cancer 3201eP Ujjwal Soni (Oklahoma City, United States of America) 局限期胰腺癌中SMAD4和HRD共突变患者的治疗选择Treatment Selection in Patients with Concurrent SMAD4 and HRD Mutations in Localized Pancreatic Cancer 3202eP Ashish Sharma (New Haven, United States of America) PDAC治疗背景下肿瘤突变负荷解读：FDA阈值仅识别1.3%无预后信号的患者，而更高TMB与化疗患者的不良生存相关Treatment-context-specific tumor mutational burden interpretation in PDAC: the FDA threshold identifies 1.3% of patients without prognostic signal, while higher TMB associates with adverse survival in chemotherapy-treated patients 3203eP Jianfeng Huang (Guangzhou, China) 脾动脉灌注化疗对比全身化疗治疗晚期胰体/尾癌的疗效与安全性：一项真实世界研究Efficacy and Safety of Splenic Artery Infusion Chemotherapy Compared With Systemic Chemotherapy in Advanced Pancreatic Body/Tail Cancer: A Real-World Study 3204eP Aniek E. Van Diepen (Maastricht, Netherlands) 晚期胰腺癌疼痛患病率与强度：一项全国性前瞻性队列研究Pain prevalence and intensity in advanced pancreatic cancer: a nationwide prospective cohort study 3205eP Stefania Gkoura (Athens, Greece) 液体活检检测不可切除胰腺癌RAS突变：与生物标志物、临床参数及肿瘤分子特征的相关性——一项前瞻性观察研究RAS Mutation Detection by Liquid Biopsy in Unresectable Pancreatic Cancer: Correlation with Biomarkers, Clinical Parameters, and Tumor Molecular Features. A Prospective Observational Study 3206eP Deema Al Zoubi (Damascus, Syria) MDCT上肿瘤-血管接触的纵向量化评估作为胰头腺癌血管侵犯及可切除性的预测指标：一项前瞻性研究Longitudinal Tumor–Vessel Contact on MDCT as a Quantitative Predictor of Vascular Invasion and Resectability in Pancreatic Head Adenocarcinoma: A Prospective Study 3207eP David L. Bajor (Cleveland, United States of America) Ivosidenib联合mFOLFIRINOX治疗可切除胰腺导管腺癌（PDA）患者的I期单中心开放标签剂量递减和扩展研究A Phase I, Single-Center, Open-Label, Dose De-escalation and Expansion Study of Ivosidenib Plus mFOLFIRINOX in Patients With Resectable Pancreatic Ductal Adenocarcinoma (PDA) 3208eP Makoto Shinoto (Chiba, Japan) 碳离子放疗治疗不可切除胰腺癌的I期剂量递增研究A phase I dose-escalation study of carbon-ion radiotherapy for unresectable pancreatic cancer 3209eP Juan Du (Nanjing, China) LAPC中NALIRIFOX对比GnP诱导化疗联合PD-1抑制剂序贯SBRT的多中心随机对照II期试验Comparison of NALIRIFOX vs GnP Induction Chemotherapy Combined with PD-1 Inhibitor followed by sequential SBRT in LAPC: A Multi-Center, Randomized Controlled, Phase II Trial 3210eP Seok Jae Huh (Busan, Republic of Korea) 胰腺癌根治性胰切除术后自体自然杀伤细胞辅助治疗联合标准化疗的I期研究延长随访结果Extended follow-up results of a phase I study of adjuvant autologous natural killer cell therapy combined with standard chemotherapy after curative pancreatectomy for pancreatic cancer. 3211eP Kuirong Jiang (Nanjing, China) 脂质体伊立替康联合奥沙利铂及S-1或5-氟尿嘧啶/亚叶酸钙辅助治疗切除术后胰腺导管腺癌：一项多中心随机II期研究Liposomal irinotecan combined with oxaliplatin and S-1 or 5-fluorouracil/leucovorin as adjuvant therapy for resected pancreatic ductal adenocarcinoma: a multicenter randomized phase II study 3212eP Shiwei Guo (Shanghai, China) NALIRIFOX治疗高危可切除胰腺癌：多中心随机开放标签研究NALIRIFOX in high-risk resectable pancreatic cancer: multicenter，randomized, open-label study 3213eP Songul Kucukcelebi (Rotterdam, Netherlands) 立体定向放疗联合IMM-101疫苗治疗少转移性胰腺癌：MEPANC试验的安全性、可行性与免疫调节结果Stereotactic Radiotherapy and IMM-101 Vaccination in Oligometastatic Pancreatic Cancer: Safety, Feasibility, and Immunomodulatory Outcomes of the MEPANC Trial 3214eP Junjie Hang (Changzhou, China) 减剂量短疗程脂质体伊立替康联合卡培他滨二线治疗晚期胰腺癌的疗效与安全性：一项多中心II期研究The Efficacy and Safety of Reduced-dose and Short-course Regimen of Liposomal Irinotecan Plus Capecitabine as Second-Line Therapy for Advanced Pancreatic Cancer: A Multicenter Phase II Study 3215eP Jiujie Cui (Shanghai, China) ALTER-PA-001试验更新结果：安罗替尼联合Benmelstobart加AG方案对比AG方案一线治疗转移性胰腺癌的多中心开放标签随机II期研究Updated Results of the ALTER-PA-001 Trial: A Multicenter, Open-Label, Randomized Phase II Study of Anlotinib Plus Benmelstobart in Combination with AG Versus AG Alone as First-Line Treatment for Metastatic Pancreatic Cancer 3216eP Nono Brano (Chongqing, China) 奥拉帕利维持治疗BRCA突变胰腺导管腺癌的临床评估：来自III期试验、真实世界证据及SEER数据库的见解Clinical Evaluation of Olaparib Maintenance Therapy in BRCA-Mutated Pancreatic Ductal Adenocarcinoma: Insights from Phase III Trials, Real-World Evidence, and the SEER Database 3217eP Giancarlo Del Gaudio (Naples, Italy) 多学科团队管理对临界可切除及局部晚期胰腺癌临床结局的影响：MDT前时代与MDT时代治疗患者的单中心对比研究Impact of Multidisciplinary Team Management on Clinical Outcomes in Borderline Resectable and Locally Advanced Pancreatic Cancer: A Single Center Comparative Study of patient treated in the Pre-MDT and MDT Era 3218eP Daniel Herrero Rivera (Madrid, Spain) 诊断与治疗延误对局限期及转移性胰腺癌的临床影响：一项西班牙多中心回顾性队列研究Clinical impact of diagnostic and treatment delays in localized and metastatic pancreatic cancer: a Spanish multicenter retrospective cohort study 3219eP Joecelyn Kirani Tan (Manchester, United Kingdom) 合并代谢共病胰腺癌死亡率的年龄分层趋势：1999至2020年美国劳动年龄人群的不成比例上升Age-Stratified Trends in Pancreatic Cancer Mortality with Co-occurring Metabolic Comorbidities: A Disproportionate Rise in Working-Age Adults in the United States, 1999 to 2020 3220eP Joecelyn Kirani Tan (Manchester, United Kingdom) 1999至2020年美国合并代谢共病的胰腺癌死亡率的种族与民族模式Racial and Ethnic Patterns in Pancreatic Cancer Mortality with Metabolic Comorbidity Co-occurrence in the United States, 1999 to 2020 3221eP Joecelyn Kirani Tan (Manchester, United Kingdom) 1999至2020年美国合并代谢共病的胰腺癌死亡率的地区及城乡模式Regional and Rural-Urban Patterns in Pancreatic Cancer Mortality with Metabolic Comorbidity Co-occurrence in the United States, 1999 to 2020 3222eP Marta M. Fudalej (Warsaw, Poland) 治疗前全身炎症指数预测胰腺癌患者死亡率的临床应用价值Clinical Utility of Pre-treatment Systemic Inflammation Indices in Predicting Mortality in Pancreatic Cancer Patients 3223eP Chien-Jui Huang (Tainan City, Taiwan) 超越D-二聚体：纤溶酶原激活物抑制剂-1（PAI-1）增强胰腺癌血栓预测及预后分层Beyond D-dimer: Plasminogen activator inhibitor-1 (PAI-1) Enhances Thrombosis Prediction and Prognostic Stratification in Pancreatic Cancer 3224eP Souhaila Akir (Rabat, Morocco) 胰腺癌胆道引流：转移性疾病是否影响ERCP成功率？Biliary Drainage in Pancreatic Cancer: Does Metastatic Disease Influence ERCP Success? 3225eP Sandra Martínez Badal (Barcelona, Spain) 胰腺癌中KRAS相关意义未明变异的功能与定量表征Functional and quantitative characterization of KRAS-associated variants of uncertain significance in pancreatic cancer 3226eP Elena Artamonova (Moscow, Russian Federation) empegfilgrastim一级预防改善转移性胰腺癌（mPC）患者FOLFIRINOX治疗后的相对剂量强度：一项系统综述与匹配调整间接比较（MAIC）结果Primary prophylaxis (PP) with empegfilgrastim improves relative dose intensity after FOLFIRINOX in metastatic pancreatic cancer (mPC) patients: results of a systematic review and matching-adjusted indirect comparison (MAIC) 3227eP Yunok Oh (Seoul, Republic of Korea) 单细胞图谱分析与AI筛选揭示STRA6为克服PDAC间质介导耐药的精准治疗靶点Single-Cell Profiling and AI-Based Screening Reveal STRA6 as a Precision Therapeutic Target to Overcome Stromal-Mediated Resistance in PDAC 3228eP Elizabeth A. Fung (Vancouver, Canada) 胰腺导管腺癌（PDAC）患者代谢共病与胚系致病变异（PGVs）的分析Analysis of metabolic comorbidities in patients with pancreatic ductal adenocarcinoma (PDAC) and pathogenic germline variants (PGVs) 3229eP Sara Durdiakova (Bratislava, Slovakia) CLDN18.2在胰腺导管腺癌中的表达及临床意义：一项荟萃分析CLDN18.2 Expression and Clinical Significance in Pancreatic Ductal Adenocarcinoma: A Meta-Analysis 3230eP Taehun Kim (Seoul, Republic of Korea) 晚期胰腺癌FOLFIRINOX诱导治疗后的化疗假期：无化疗间期（CFI）时长的可行性及预测因素Chemotherapy Holiday After Induction FOLFIRINOX in Advanced Pancreatic Cancer: Feasibility and Predictors of Chemotherapy-Free Interval (CFI) Length 3231eP Ditila Doracaj (Tirana, Albania) 阿尔巴尼亚胰腺导管腺癌代谢功能障碍的临床病理学关联Clinicopathological associations of metabolic dysfunction in pancreatic ductal adenocarcinoma in Albania 3232eP Yang Liu (Tianjin, China) 晚期胰腺导管腺癌不可逆电穿孔治疗后CA19-9的早期控制Early CA19-9 control after irreversible electroporation in advanced pancreatic ductal adenocarcinoma 3233eP Peter Hosein (Miami, United States of America) ELI-002 7P mKRAS T细胞调节后转移性胰腺癌的根治Eradication of metastatic pancreatic cancer after ELI-002 7P mKRAS T cell modulation 3234eP Bruno Buecher (Paris, France, CEDEX 5) 胰腺导管腺癌多基因Panel检测的法国推荐意见French recommendations on multigene panel testing in pancreatic ductal adenocarcinoma 3235eP Xiaofeng Xue (Suzhou, China) 胰管内支架不能降低临床相关术后胰瘘但增加胰切除术后急性胰腺炎：一项倾向评分匹配分析Internal pancreatic duct stents do not reduce clinically relevant postoperative pancreatic fistula but increase post-pancreatectomy acute pancreatitis: A propensity score-matched analysis 3236eP Xu Pan (Beijing, China) 胰腺导管腺癌的大规模单细胞空间解析Large-Scale Single-Cell Spatial Dissection of Pancreatic Ductal Adenocarcinoma 3237eP Kreina S. Vega Cano (Barcelona, Spain) 晚期胰腺癌（APC）中基于5-氟尿嘧啶（5FU）和吉西他滨（GEM）化疗获益差异的表型特征Phenotypes of differential benefit from 5-fluorouracil (5FU) and gemcitabine (GEM) based chemotherapy in Advanced Pancreatic Cancer (APC) 3238eP Hsin Hui Wang (Taipei City, Taiwan) 靶向TXNDC5重塑促结缔组织增生及代谢微环境并使PDAC对PD-1阻断敏感Targeting TXNDC5 reshapes the desmoplastic and metabolic landscape and sensitizes PDAC to PD-1 blockade 3239eP Daniele Santini (Latina, Italy) 转移性胰腺导管腺癌（mPDAC）的治疗（Tx）策略：来自跨国基于实践与证据的筛查和共识（SCOPE）焦点小组的结果Treatment (Tx) strategies to manage metastatic pancreatic ductal adenocarcinoma (mPDAC): Results from the multinational Screening and COnsensus based on Practices and Evidence (SCOPE) focus groups 3240eP Anika Forstreuter (Hamburg, Germany) 超越BMI：骨骼肌与内脏脂肪作为胰腺癌的独立预后标志物Beyond BMI: skeletal muscle and visceral fat as independent prognostic markers in pancreatic cancer 3241eP Sacha El Khoury (Houston, United States of America) PDAC中CLDN18.2的表达：不依赖KRAS状态及IV期的预后价值CLDN18.2 Expression in PDAC: KRAS Independence and Stage IV Prognostic Value 3242eP Daryna Bulakh (Kaunas, Lithuania) OXTR rs53576基因多态性在胰腺癌中的预后价值Prognostic Value of the OXTR rs53576 gene polymorphism in Pancreatic Cancer 3243eP Hyo Shik Shin (Seoul, Republic of Korea) 肿瘤相关巨噬细胞来源的CXCL16在胰腺导管腺癌中的作用Role of tumor-associated macrophage-derived CXCL16 in pancreatic ductal adenocarcinoma 3244eP Hila Fishman (Haifa, Israel) 肿瘤电场治疗（TTFields）联合FOLFIRINOX或KRAS抑制剂治疗胰腺癌的临床前评估Preclinical evaluation of Tumor Treating Fields (TTFields) with FOLFIRINOX or KRAS inhibition in pancreatic cancer 3245eP Marine Valery (Villejuif, France) 胰腺和肝脏肿瘤加速诊断路径的影响：Gustave Roussy癌症中心多学科胃肠肿瘤团队的经验Impact of an Accelerated Diagnostic Pathway for Pancreatic and Hepatic Tumors: Experience from a Multidisciplinary Gastro-intestinal Oncology team at Gustave Roussy Cancer Center. 3246eP Akhil Deepak Vatvani (Tangerang, Indonesia) 直接口服抗凝药对比低分子肝素用于接受FOLFIRINOX治疗的胰腺腺癌患者：一项倾向评分匹配的真实世界分析Direct Oral Anticoagulants Versus Low-Molecular-Weight Heparin in Pancreatic Adenocarcinoma Patients Receiving FOLFIRINOX: A Propensity-Matched Real-World Analysis 3247eP Carol Cremin (Vancouver, Canada) 携带ATM胚系致病变异的胰腺导管腺癌的临床特征与结局：一项回顾性分析Clinical characteristics and outcomes of pancreatic ductal adenocarcinoma with germline pathogenic ATM variants: a retrospective analysis 3248eP Leonardo E. Da Cunha (Sao Jose do Rio Preto, Brazil) FOLFIRINOX对比吉西他滨联合白蛋白紫杉醇一线治疗转移性胰腺癌：真实世界证据的系统综述与荟萃分析First-line FOLFIRINOX versus Gemcitabine plus Nab-Paclitaxel for Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis of Real-World Evidence 3249eP Daniela Iacono (Rome, Italy) 瘤内磷-32微粒（OncoSil®）治疗不可切除局部晚期胰腺腺癌患者的真实世界经验Intratumoral phosphorus-32 microparticles (OncoSil®) in unresectable locally advanced pancreatic adenocarcinoma patients: a real-world experience 3250eP Antoine Jourdain (Paris, France) 胰腺癌确诊时的营养不良、肌少症、高代谢及微量营养素缺乏：NUTRIPAN队列Malnutrition, sarcopenia, hypermetabolism and micronutrient deficiencies at pancreatic cancer diagnosis: the NUTRIPAN cohort 3251eP Ana Paula O. Victorino (Rio de Janeiro, Brazil) 适合序贯治疗的晚期胰腺癌患者的总生存：巴西真实世界数据Overall survival in advanced pancreatic cancer patients eligible for sequential treatment: real-world data from in Brazil 3253eP Navindi De Silva (Vancouver, Canada) 标准与改良吉西他滨/白蛋白紫杉醇给药方案在转移性胰腺癌中的真实世界生存结局Real-World Survival Outcomes Associated with Standard Versus Modified Gemcitabine/Nab-Paclitaxel Dosing Schedules in Metastatic Pancreatic Cancer 3254eP Ana Paula O. Victorino (Rio de Janeiro, Brazil) 晚期胰腺癌的治疗机会丧失：巴西真实世界队列中的早期死亡模式、基线危险因素及快速进展者特征Treatment opportunity loss in advanced pancreatic cancer: early mortality patterns, baseline risk factors, and characterization of rapid progressors in a brazilian real-world cohort 3255eP Jesus Rodriguez Pascual (Madrid, Spain) 晚期胰腺癌的治疗顺序安排：一项大规模真实世界分析Treatment sequencing in advanced pancreatic cancer: a large real-world analysis 3256eP Joecelyn Kirani Tan (Manchester, United Kingdom) 美国合并代谢共病的胰腺癌死亡率二十年全国趋势：一项基于人群的横断面分析（1999–2020）Two-Decade National Trends in Pancreatic Cancer Mortality with Metabolic Comorbidities in the United States: A Population-Based Cross-Sectional Analysis (1999–2020) 3257eP Diyora Kurambaeva (Tashkent, Uzbekistan) 胰腺癌手术根治性的个体化把握：标准切除与解剖靶向切除的荟萃分析与系统综述Tailoring Surgical Radicality in Pancreatic Cancer: A Meta-Analysis and Systematic Review of Standard versus Anatomically Targeted Resections 3258eP Sergio Perez-Fernandez (Barcelona, Spain) 胰腺导管腺癌根治性切除术后复发的多维分析Multidimensional analysis of recurrence after curative-intent resection of pancreatic ductal adenocarcinoma. 3259eP Maryam Taherioun Isfahani (Tehran, Iran) 临界可切除或局部晚期胰腺导管腺癌新辅助治疗后的手术时机：系统综述与荟萃分析Surgical Timing After Neoadjuvant Therapy in Borderline Resectable or Locally Advanced Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis 3260eP Patricia Capdevila Gaudens (Valencia, Spain) 从临界可切除到可切除：胰腺腺癌新辅助治疗后谁真正接受了手术From borderline to resectable: who truly reaches surgery after neoadjuvant therapy for pancreatic adenocarcinoma 3261eP Blanca María Fernández Bellón (Madrid, Spain) 光子计数探测器CT用于胰腺肿瘤：诊断准确性、图像质量及辐射剂量的系统综述与荟萃分析Photon-counting detector CT for pancreatic neoplasms: a systematic review and meta-analysis of diagnostic accuracy, image quality, and radiation dose 3262eP Yasmin B. Da Cruz (Curitiba, Brazil) 非转移性胰腺导管腺癌根治性手术的利用不足：来自SEER分析的社会经济与种族决定因素Underutilization of Curative-Intent Surgery in Non-Metastatic Pancreatic Ductal Adenocarcinoma: Socioeconomic and Racial Determinants from a SEER Analysis 3263eP Xiaofei Zhang (Shanghai, China) 戈沙妥珠单抗治疗多线经治晚期胰腺癌的预后因素与安全性Prognostic factors and safety of sacituzumab govitecan in heavily pretreated advanced pancreatic cancer 3264eP Xuyao Zhang (Shanghai, China) 靶向PD-1和IL-18R的三特异性抗体在胰腺癌中以更优安全性增强抗肿瘤免疫Trispecific Antibody Targeting PD-1 and IL-18R Enhances Antitumor Immunity with Superior Safety Profile in Pancreatic Cancer 3265eP Burak Alper Zengin (Istanbul, Türkiye) 早发转移性胰腺癌的临床特征与生存结局Clinical Characteristics and Survival Outcomes in Early-Onset Metastatic Pancreatic Cancer 3266eP Ravi Kumar Paluri (Winston-Salem, United States of America) 循环microRNA纵向动态变化作为胰腺癌诱导化疗联合SBRT治疗后应答及生存的探索性预测指标Longitudinal circulating microRNA dynamics as exploratory predictors of response and survival in pancreatic cancer treated with induction chemotherapy followed by SBRT 3267eP Alihan Altunay (Antalya, Türkiye) 临界可切除胰腺癌的新辅助化疗：临床结局及其与CT肿瘤密度的关联Neoadjuvant Chemotherapy in Borderline Resectable Pancreatic Cancer: Clinical Outcomes and association with CT Tumor Density 3268eP Sehyun Park (Szeged, Hungary) 微创对比开放胰切除术治疗可切除胰腺导管腺癌的肿瘤学结局：系统综述与荟萃分析Oncologic Outcomes of Minimally Invasive Versus Open Pancreatectomy for Resectable Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis 3269eP Mutiu Jimoh (Lagos, Nigeria) 私立医疗机构中的胰腺癌：尼日利亚拉各斯的治疗与生存结局——十年回顾Pancreatic Cancer in Private Care: Treatment _ Survival Outcomes from Lagos, Nigeria – A 10-Year Review 3270eP Jiayue Zou (Suzhou, China) 术前活化部分凝血活酶时间作为初始切除胰腺导管腺癌早期复发及生存的独立预测因子Preoperative activated partial thromboplastin time as an independent predictor of early recurrence and survival in upfront resected pancreatic ductal adenocarcinoma 3272eTiP Haiqi Lu (Hangzhou, China) 优替德隆注射液治疗标准治疗难治的晚期胰腺癌的单臂探索性临床试验A single-arm exploratory clinical trial of Utidelone injection for advanced pancreatic cancer refractory to standard therapy 3273eTiP Einar Sulheim (Oslo, Norway) PS101声学簇疗法联合化疗治疗局部晚期胰腺癌（ENACT试验）PS101 in Acoustic Cluster Therapy with Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer (ENACT trial) ∞ EPILOGUE写在最后胰腺癌是本届 ESMO 变化最剧烈的瘤种：三年前 KRAS 还只是转化研究的题目，如今已经有 III 期、有围手术期设计、有疫苗平台。但也要保持清醒——胰腺癌的临床决策仍然高度依赖体能状态与营养支持，新药能否真正改变生存曲线，还要看随后的 III 期读出。「KRAS 之后，胰腺癌需要的是能进入一线、进入围手术期的完整证据链，而不只是漂亮的早期缓解率。」 END 本文数据整理自 ESMO Congress 2026 官方公开日程（含 LBA 及专场报道），中文题目为 AI 辅助翻译，仅供检索参考，请以英文原文为准。如果你觉得今天这篇有收获，欢迎点赞、在看、转发三连，See You！扫码关注我，上学堂呦版权声明：本平台旨在帮助医疗卫生专业人士更好地了解相关疾病领域最新进展。本平台对发布的资讯内容，并不代表同意其描述和观点，仅为提供更多信息。如该等信息被用于了解资讯以外的目的，本平台及作者不承担相关责任。若涉及版权问题，烦请权利人与我们联系，我们将尽快处理。仅供医疗卫生专业人士为了解资讯使用，该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议。

2026-10-02

·医药魔方ByDrug

TLR7激动剂+抗PD-L1+NA三联疗法可加强病毒抑制慢乙肝患者HBsAg下降

TQ-A3334是一款由正大天晴公司开发用于慢性乙型肝炎治疗的选择性TLR7激动剂，TQ-A3334 通过激活Toll样受体（TLR）-7 以诱导特异性细胞因子和趋化因子（例如IFN-α 和 IFN诱导型蛋白-10（IP-10））从而抑制HBV。 TQ-B2450是一种人源化程序性死亡配体1（PD-L1）抗体，可恢复T细胞功能。研究人员进行了一项前瞻性、2期、单中心、开放标签RCT（ OCEANcure05 RCT研究），以评估TLR7激动剂TQ-A3334 单独或与PD-L1抗体TQ-B2450 联合在稳定NAs治疗且HBsAg水平在250 IU/mL至5000 IU/mL之间的CHB患者中的安全性、疗效和免疫学特征。

100 项与贝莫苏拜单抗相关的药物交易

登录后查看更多信息

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
肺泡软组织肉瘤	中国	正大天晴药业集团南京顺欣制药有限公司	2026-04-14
晚期鳞状非小细胞肺癌	中国	正大天晴药业集团南京顺欣制药有限公司	2026-02-10
非小细胞肺癌 III期	中国	正大天晴药业集团南京顺欣制药有限公司	2026-02-10
转移性肾细胞癌	中国	正大天晴药业集团南京顺欣制药有限公司	2025-05-13
不可切除的肾细胞癌	中国	正大天晴药业集团南京顺欣制药有限公司	2025-05-13
子宫内膜癌	中国	正大天晴药业集团南京顺欣制药有限公司	2024-11-22
广泛期小细胞肺癌	中国	正大天晴药业集团南京顺欣制药有限公司	2024-04-30

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
错配修复缺陷子宫内膜癌	临床3期	中国	正大天晴药业集团股份有限公司	2024-09-05
转移性子宫内膜恶性肿瘤	临床3期	中国	正大天晴药业集团股份有限公司	2024-07-01
复发性铂耐药性卵巢癌	临床3期	中国	正大天晴药业集团股份有限公司	2021-09-26
转移性非小细胞肺癌	临床3期	中国	正大天晴药业集团股份有限公司	2021-08-06
鳞状非小细胞肺癌	临床3期	中国	正大天晴药业集团股份有限公司	2021-08-06
晚期非小细胞肺癌	临床3期	中国	正大天晴药业集团股份有限公司	2021-07-21
非小细胞肺癌	临床3期	中国	正大天晴药业集团股份有限公司	2021-07-21
非鳞状非小细胞肺癌	临床3期	中国	正大天晴药业集团股份有限公司	2021-07-21
晚期胆道癌	临床3期	中国	正大天晴药业集团股份有限公司	2021-01-26
晚期肾细胞癌	临床3期	中国	正大天晴药业集团股份有限公司	2020-08-25

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


WCLC2026	临床2期	小细胞肺癌维持	20	induction therapy: benmelstobart plus planlotinibsed chemotherapy + maintenance therapy: benmelstobart plus anlotinib (patients who had not progressed after induction therapy)	網淵衊顧築積餘鑰構壓(簾構鑰選壓艱製糧鬱製) = 淵餘淵蓋積蓋鏇繭膚夢鏇餘鹹鏇積願壓製壓廠 (範蓋壓醖艱觸製夢遞鹽, 6.5 ~ NR) 更多	积极	2026-09-12
NCT06637163 (ASCO2026)	临床2期	食管鳞状细胞癌新辅助	82	BEN+cCRT	積憲範鑰積築網鏇膚壓(廠鏇築廠窪齋積獵廠夢) = 鏇鹹衊醖醖顧壓窪鑰襯積鹹願鏇糧淵壓鏇顧襯 (獵襯餘選鹽壓鏇糧積艱 ) 更多	积极	2026-05-29
				cCRT	積憲範鑰積築網鏇膚壓(廠鏇築廠窪齋積獵廠夢) = 膚齋憲夢顧觸範糧獵壓積鹹願鏇糧淵壓鏇顧襯 (獵襯餘選鹽壓鏇糧積艱 ) 更多
ASCO2026	临床2期	局部晚期头颈部鳞状细胞癌新辅助	36	Benmelstobart + Anlotinib + Chemotherapy	壓蓋鑰鑰構積獵鬱襯淵(鏇製糧夢鑰獵鏇夢鏇醖) = 遞夢鹹網願鑰衊鬱選顧襯膚壓繭糧顧顧蓋鬱積 (憲鏇獵網鏇鑰顧製蓋鑰, 66.3 ~ 95.8) 更多	积极	2026-05-29
NCT06662006 (ASCO2026)	临床2期	转移性胰腺导管腺癌二线	46	NAL-IRI/5-FU/LV + benmelstobart + anlotinib (Cohort A)	襯艱壓憲鬱窪範繭醖蓋(積窪願鏇製鬱簾齋衊願) = 餘顧淵網衊繭鹹壓餘膚積積顧鑰積糧糧鹹鏇願 (醖繭觸顧獵糧餘襯築鹽, 1.9 ~ 32.9) 更多	积极	2026-05-29
				NAL-IRI/5-FU/LV + benmelstobart + anlotinib (Cohort B)	襯艱壓憲鬱窪範繭醖蓋(積窪願鏇製鬱簾齋衊願) = 窪構製鹽選襯鬱製觸網積積顧鑰積糧糧鹹鏇願 (醖繭觸顧獵糧餘襯築鹽, 12.0 ~ 64.9) 更多
NCT04964479 (CAMPASS, Pubmed \| Lancet Oncol)	临床3期	PD-L1阳性非小细胞肺癌一线 PD-L1-positive	531	Benmelstobart plus Anlotinib	膚齋膚夢蓋夢襯衊構築(鏇膚餘衊築積繭夢廠築) = 遞夢製醖糧糧觸膚窪壓鑰艱憲餘鹽齋廠觸壓壓 (憲製艱網觸齋選獵製憲, 9.2 ~ 12.6) 更多	积极	2026-04-01
				Pembrolizumab plus Placebo	憲鑰簾選夢艱蓋餘衊鹹(憲願醖艱觸範製齋艱積) = 壓繭壓鑰顧廠淵壓繭衊糧夢蓋齋選艱網膚衊衊 (蓋顧廠網鏇鏇蓋醖顧糧 ) 更多
NCT04964479 (CAMPASS, Pubmed) 人工标引	临床3期	PD-L1阳性非小细胞肺癌一线 PD-L1 Positive	531	Benmelstobart + Anlotinib	遞餘顧觸獵蓋壓壓鬱鹹(遞構窪獵膚艱製糧窪蓋) = 餘壓鹹鬱繭觸範醖齋鏇艱繭鹹構廠廠遞淵積獵 (積鑰願壓積鹹鹽衊網獵, 9.2 ~ 12.6) 更多	积极	2026-03-10
				Pembrolizumab + Placebo	遞餘顧觸獵蓋壓壓鬱鹹(遞構窪獵膚艱製糧窪蓋) = 繭願願鹹願鹹範鬱顧網艱繭鹹構廠廠遞淵積獵 (積鑰願壓積鹹鹽衊網獵, 5.8 ~ 9.5) 更多
NCT06621095 (ALTER-PA-001, NEWS) 人工标引	临床2期	转移性胰腺癌一线	38	安罗替尼+贝莫苏拜单抗+白蛋白结合型紫杉醇+吉西他滨	築積遞繭憲築衊願膚糧(製襯鬱獵選鑰鏇夢憲憲) = 憲膚憲淵繭齋夢獵醖製網糧憲壓餘憲壓製遞鹽 (構廠願觸壓糧鹽鹹衊鏇 ) 更多	积极	2026-01-15
				白蛋白结合型紫杉醇+吉西他滨	築積遞繭憲築衊願膚糧(製襯鬱獵選鑰鏇夢憲憲) = 壓獵夢遞範製觸鹹鏇齋網糧憲壓餘憲壓製遞鹽 (構廠願觸壓糧鹽鹹衊鏇 ) 更多
NCT06637163 (ASCO_GI2026) 人工标引	临床2期	食管鳞状细胞癌新辅助	82	Benmelstobart + Concurrent Chemoradiotherapy	築夢憲鏇艱積顧構齋築(蓋廠願構淵襯範鹽遞積) = 蓋壓製蓋窪繭憲遞廠餘膚壓製鏇淵蓋鬱築願齋 (糧積齋繭衊鹹鹹選選淵 ) 更多	积极	2026-01-08
				Concurrent Chemoradiotherapy	築夢憲鏇艱積顧構齋築(蓋廠願構淵襯範鹽遞積) = 糧網遞膚繭淵選鹽壓構膚壓製鏇淵蓋鬱築願齋 (糧積齋繭衊鹹鹹選選淵 ) 更多
NCT04895345 (Pubmed \| Med)	临床2期	复发性鼻咽癌	25	TQB2450 (Intensity-Modulated Radiotherapy)	壓獵製構艱製憲鬱膚壓(鬱憲廠鏇衊糧糧顧觸鏇) = 餘廠鏇齋範蓋衊窪製衊廠構齋構蓋鹽鏇餘構選 (鑰夢鬱觸襯鹽顧膚網糧, 50.6 ~ 87.9) 更多	积极	2025-11-01
NCT04895345 (ESMO2025)	临床2期	复发性鼻咽癌	25	TQB2450 (intensity-modulated radiotherapy)	鹹糧積鹹顧淵憲獵遞觸(顧觸廠築糧壓遞膚鑰窪) = 餘遞鹽築獵夢遞衊鑰觸淵廠製窪遞範淵膚網窪 (網繭蓋夢製鹹築積餘遞, 50.6 ~ 87.9) 更多	积极	2025-10-17